Hamburg-based AI pathology startup Mindpeak raised $15.3M in Series A led by ZEISS Ventures and Inno...
The AMW Read
The article updates the player map for the AI pathology sub-segment and exemplifies the pattern of CVC-led strategic convergence between imaging hardware giants and AI software providers.
Hamburg-based AI pathology startup Mindpeak raised $15.3M in Series A led by ZEISS Ventures and InnoVentureFund, with participation from AI.FUND and the European Innovation Council Fund. Founded in 2018, Mindpeak's algorithms have already supported 30,000+ patient diagnoses in routine clinical use across the US and EU, delivering pixel-level tissue analysis for breast and lung cancer. This CVC-led round signals a strategic convergence where imaging hardware giants like ZEISS are vertically integrating AI software into their digital pathology ecosystem, leveraging optics expertise to accelerate adoption. Post-funding, Mindpeak has rapidly scaled partnerships with AstraZeneca, Epredia, PathGroup, and Techcyte, positioning its platform at the center of AI-driven precision medicine infrastructure.